Treatment of Peyronie’s Disease in the Active Phase

The most important stage that many patients miss: the active phase of Peyronie’s disease is the period when inflammatory activity is still present in the tissues and the plaque continues to form.
At this stage, the goal of treatment is not simply to observe the process, but to timely target the pathological tissue in order to stop disease progression.

It is during the period of fibrous plaque formation that there is still an opportunity to influence the course of the disease, reduce the risk of pronounced deformity, and avoid more complex treatment in the future.

What Is the Active Phase of Peyronie’s Disease

Peyronie’s disease develops gradually. In the early stage, an inflammatory reaction occurs in the tunica albuginea of the penis, followed by the formation of fibrous tissue and plaque. This period is referred to as the active phase of the disease.

The active phase may be characterized by:

pain or discomfort during erection
appearance of a lump or plaque
changes in penile shape
increasing curvature
reduction in length
deterioration in erection quality

The active phase usually lasts from several months up to 12–18 months, although the duration may vary among patients. While the plaque is still forming, the disease remains dynamic. It is during this period that treatment is most timely.

Main Treatment Goals in the Active Phase

Treatment in the active phase of Peyronie’s disease is aimed not only at reducing symptoms but also at targeting the underlying pathological process.

Goals:

reduction of inflammatory activity
slowing or stopping the progression of fibrosis
targeting the forming fibrous plaque
reducing the risk of pronounced deformity
preservation of erectile function
reducing the likelihood of progression to more severe forms of the disease

How We Target the Disease in the Active Phase

In the active phase, Professor Knigavko’s protocol uses biocompatible collagenase as part of a more comprehensive treatment strategy.
Its purpose is to target the forming plaque at a stage when pathological collagen is still amenable to correction.

Injection Therapy Injection Therapy Injection-based methods allow targeted action directly on the area of the fibrous plaque. At this stage, the goal of treatment is to stop further formation of pathological tissue, influence the structure of the plaque, and reduce the severity of deformity.

Biocompatible Collagenase One of the key treatment approaches in the active phase is the use of collagenase to target fibrous tissue. Unlike a wait-and-see approach, this method focuses on treating the plaque at a stage when it is still forming and remains more responsive to correction.

Anti-inflammatory Action In the presence of active inflammation, methods aimed at reducing the inflammatory response and alleviating pain may be used. This is especially important at an early stage, when the pathological process has not yet completed and remains clinically active.

Tissue Biostimulation PRP, cell-based technologies, and exosomes may be used as part of comprehensive treatment in the active phase. Their purpose is to support tissue regeneration, reduce pathological scarring, and promote a more favorable healing pathway.

Traction Therapy PeyroFix traction therapy is used to support proper tissue architecture and stabilize treatment results. It helps address not only deformity but also the tendency toward penile shortening.

The strength of treatment in the active phase lies not in a single method, but in the precise combination of multiple approaches.

Professor Knigavko’s protocol integrates plaque-targeted therapy, inflammation control, regenerative support, and result stabilization into a unified system.

More Affordable Than the Standard Xiaflex Approach

One of the reasons patients delay injection-based treatment is the high cost of standard Xiaflex regimens.
The Collagenase+ protocol is considered a more comprehensive and more affordable option for treatment in the active phase.

Rehabilitation and Support After Treatment

Treatment of Peyronie’s disease in the active phase does not end with the procedure itself. To achieve a stable result, patient follow-up and tissue support after the main stage of treatment are essential.

The supportive phase includes:

monitoring the dynamics of the plaque and deformity
adjusting further treatment strategy depending on tissue response
traction therapy
methods aimed at proper tissue healing
measures to preserve erectile function
individual recommendations regarding sexual activity and recovery

The goal of post-treatment rehabilitation is to stabilize the achieved result and reduce the risk of recurrence. To support erectile quality and preserve maximum possible function.

Continuous follow-up after treatment is just as important to the outcome as the intervention on the plaque itself.

Before and after Peyronie’s disease treatment

We share results of Peyronie’s disease treatment, including collagenase therapy, on our Telegram channel

If the Disease Has Already Progressed to a Later Stage

Not all patients are diagnosed during the active phase. If the deformity has already become pronounced, the plaque has calcified, or erectile function has significantly worsened, this does not mean that treatment is no longer possible.

In such cases, other treatment options are considered, including microsurgical correction methods.